Once laser-focused on liver, MiNA takes swing at neurology with Servier's backing
Once focused on hard-to-treat liver diseases, MiNA Therapeutics is joining forces with Servier to engage its small activating RNA technology on another difficult front: neurology.
MiNA and Servier announced a new research alliance Thursday centered around neurological disorders. While the partners are keeping quiet about their targets for now, MiNA CEO Robert Habib vaguely revealed that the first one was nominated by Servier, which has an option over it. MiNA stands to receive up to $266.3 million (€220 million) in an upfront payment and milestones on that target alone, though they declined to break those numbers down any further.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.